These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 31607412)
1. Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Al-Janabi A; El Nokrashy A; Sharief L; Nagendran V; Lightman S; Tomkins-Netzer O Ophthalmology; 2020 Mar; 127(3):410-416. PubMed ID: 31607412 [TBL] [Abstract][Full Text] [Related]
2. Long-term Experience with Anti-tumor Necrosis factor - α Therapy in the Treatment of Refractory, Non-infectious Intermediate, Posterior, and Panuveitis. Corredores Dieb J; Vofo B; Amer R Ocul Immunol Inflamm; 2024 Aug; 32(6):932-939. PubMed ID: 36538811 [TBL] [Abstract][Full Text] [Related]
3. Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results. Jaffe GJ; Lin P; Keenan RT; Ashton P; Skalak C; Stinnett SS Ophthalmology; 2016 Sep; 123(9):1940-8. PubMed ID: 27421623 [TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. Suhler EB; Adán A; Brézin AP; Fortin E; Goto H; Jaffe GJ; Kaburaki T; Kramer M; Lim LL; Muccioli C; Nguyen QD; Van Calster J; Cimino L; Kron M; Song AP; Liu J; Pathai S; Camez A; Schlaen A; van Velthoven MEJ; Vitale AT; Zierhut M; Tari S; Dick AD Ophthalmology; 2018 Jul; 125(7):1075-1087. PubMed ID: 29429764 [TBL] [Abstract][Full Text] [Related]
5. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Suhler EB; Jaffe GJ; Fortin E; Lim LL; Merrill PT; Dick AD; Brezin AP; Nguyen QD; Thorne JE; Van Calster J; Cimino L; Adan A; Goto H; Kaburaki T; Kramer M; Vitale AT; Kron M; Song AP; Liu J; Pathai S; Douglas KM; Schlaen A; Muccioli C; Van Velthoven MEJ; Zierhut M; Rosenbaum JT Ophthalmology; 2021 Jun; 128(6):899-909. PubMed ID: 33157077 [TBL] [Abstract][Full Text] [Related]
6. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials. Sheppard J; Joshi A; Betts KA; Hudgens S; Tari S; Chen N; Skup M; Dick AD JAMA Ophthalmol; 2017 Jun; 135(6):511-518. PubMed ID: 28426849 [TBL] [Abstract][Full Text] [Related]
7. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. ; Kempen JH; Altaweel MM; Drye LT; Holbrook JT; Jabs DA; Sugar EA; Thorne JE Ophthalmology; 2015 Oct; 122(10):1967-75. PubMed ID: 26298715 [TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. ; Kempen JH; Altaweel MM; Holbrook JT; Jabs DA; Louis TA; Sugar EA; Thorne JE Ophthalmology; 2011 Oct; 118(10):1916-26. PubMed ID: 21840602 [TBL] [Abstract][Full Text] [Related]
9. A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. Squires H; Poku E; Bermejo I; Cooper K; Stevens J; Hamilton J; Wong R; Denniston A; Pearce I; Quhill F Health Technol Assess; 2017 Nov; 21(68):1-170. PubMed ID: 29183563 [TBL] [Abstract][Full Text] [Related]
10. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Nussenblatt RB; Peterson JS; Foster CS; Rao NA; See RF; Letko E; Buggage RR Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055 [TBL] [Abstract][Full Text] [Related]
11. Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials. Suhler EB; Thorne JE; Mittal M; Betts KA; Tari S; Camez A; Bao Y; Joshi A Ophthalmology; 2017 Dec; 124(12):1799-1807. PubMed ID: 28689898 [TBL] [Abstract][Full Text] [Related]
12. Longitudinal Vision-Related Quality of Life for Patients with Noninfectious Uveitis Treated with Fluocinolone Acetonide Implant or Systemic Corticosteroid Therapy. Sugar EA; Venugopal V; Thorne JE; Frick KD; Holland GN; Wang RC; Almanzor R; Jabs DA; Holbrook JT; Ophthalmology; 2017 Nov; 124(11):1662-1669. PubMed ID: 28624167 [TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Fabiani C; Vitale A; Rigante D; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Gentileschi S; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L Clin Rheumatol; 2019 Feb; 38(2):407-415. PubMed ID: 30099655 [TBL] [Abstract][Full Text] [Related]
14. Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis. ; Kempen JH; Altaweel MM; Holbrook JT; Sugar EA; Thorne JE; Jabs DA JAMA; 2017 May; 317(19):1993-2005. PubMed ID: 28477440 [TBL] [Abstract][Full Text] [Related]
15. Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study. Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group Ophthalmology; 2015 Oct; 122(10):1976-86. PubMed ID: 26298718 [TBL] [Abstract][Full Text] [Related]
16. Oral corticosteroid exposure and increased risk of related complications in patients with noninfectious intermediate, posterior, or panuveitis: Real-world data analysis. Chirikov VV; Shah R; Kwon Y; Patel D Ophthalmic Epidemiol; 2019 Feb; 26(1):27-46. PubMed ID: 30199301 [TBL] [Abstract][Full Text] [Related]
17. Outcome of Treating Pediatric Uveitis With Dexamethasone Implants. Tomkins-Netzer O; Talat L; Seguin-Greenstein S; Bar A; Lightman S Am J Ophthalmol; 2016 Jan; 161():110-5.e1-2. PubMed ID: 26478217 [TBL] [Abstract][Full Text] [Related]
18. Effect of a Fluocinolone Acetonide Insert on Recurrence Rates in Noninfectious Intermediate, Posterior, or Panuveitis: Three-Year Results. Jaffe GJ; Pavesio CE; Ophthalmology; 2020 Oct; 127(10):1395-1404. PubMed ID: 32624244 [TBL] [Abstract][Full Text] [Related]
19. Adalimumab for the treatment of refractory active and inactive non-infectious uveitis. Lee JT; Yates WB; Rogers S; Wakefield D; McCluskey P; Lim LL Br J Ophthalmol; 2018 Dec; 102(12):1672-1678. PubMed ID: 29459430 [TBL] [Abstract][Full Text] [Related]
20. Incidence and Outcome of Uveitic Glaucoma in Eyes With Intermediate, Posterior, or Panuveitis Followed up to 10 Years After Randomization to Fluocinolone Acetonide Implant or Systemic Therapy. Kempen JH; Van Natta ML; Friedman DS; Altaweel MM; Ansari H; Dunn JP; Elner SG; Holbrook JT; Lim LL; Sugar EA; Jabs DA; Am J Ophthalmol; 2020 Nov; 219():303-316. PubMed ID: 32628922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]